PATENT CLAIM ANALYSIS

Application Number: 15884221
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["435", "006100"]

Abstract:
A method for predicting the responsiveness of a patient having a hematological cancer to a treatment compound, comprising obtaining a biological sample from the patient having the hematological cancer; determining the expression level of one, two, three, four, five, or more genes; and comparing the expression level of the one, two, three, four, five, or more genes in the biological sample with a reference expression level of the same genes, wherein the treatment compound is 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (lenalidomide), 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione (Compound A), or a stereoisomer, pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or a polymorph thereof.

Claim (Index 71):
A kit for predicting the responsiveness of a patient having a hematological cancer to a treatment compound, comprising an agent for determining the expression levels of the genes selected from the groups consisting of:\n (i) BICC1, C10orf54, C1RL, C20orf112, C8orf4, CCDC88C, CD97, CEBPB, CFB, CHRDL1, CIRH1A, CPSF3, CSF1R, DDR2, DLGAP5, DUSP1, EMR2, EPB41L3, FBXO32, GAS2L1, GINS4, IFITM2, KCNMB1, LGALS3BP, LRP11, MEGF6, MEIS1, MYO1F, PDGFC, PRNP, PTPRM, RAB31, RBBP8, RUVBL1, SEMA3C, SERPING1, SMOC2, SNRPD1, TBC1D2B, THEMIS2, TMEM173, TPSAB1, TRIP13, TXNIP, ULK1, WDR12, WWTR1, XAF1, ZNF215, (ii) ALKBH2, AOAH, C10orf54, C1RL, C8orf4, CD84, CD97, CDC20, CEBPB, CEBPD, CHRDL1, CIRH1A, CPSF3, CYP1B1, FBXO32, FOSL2, GAS2L1, GBP3, GINS4, GNAQ, GPR155, GPRIN3, HJURP, KCNMB1, LRP11, MAFB, MEGF6, MEIS1, MYO1F, MYOF, PCSK5, PDGFC, PHACTR2, PTPRM, RAB31, RALGDS, RUVBL1, SASH1, SERPING1, SMOC2, SNRPD1, SSH1, TBC1D2B, TMEM173, TP53INP2, TRIP13, ULK1, WWTR1, XAF1, ZNF215, (iii) C10orf54, C1RL, C20orf112, C8orf4, CCDC88C, CILP, CIRH1A, CLU, CPVL, CSF1R, CTSB, EPB41L3, FBXO32, IFI44, LRP11, MEGF6, MEIS1, PLAT, SERPING1, SPC25, THEMIS2, TPSAB1, ULK1, XAF1, ZNF215, and/or (iv) C10orf54, C1RL, C20orf112, C8orf4, CCNB1, CDC6, CILP, CLU, CPSF3, CPVL, CSF1R, CTSB, EPB41L3, FBXO32, IFI44, MEIS1, PHACTR2, PLAT, RUVBL1, SERPING1, SNRPD1, TRIP13, XAF1, ZNF215, or a subset thereof in a biological sample obtained from the patient prior to the compound treatment, wherein the treatment compound is 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (lenalidomide), 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione (Compound A), or a stereoisomer, pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or a polymorph thereof.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 86.0
- Lexical Diversity: 2.15
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15273205', '13459005', '15150227', '14381004', '13417088']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5584801733377536
- 35 USC 102 Novelty (BERT): 0.5968808171586243
- Combined Prediction Score: 0.5623202377198406
- Mean Citation Score: 308.514826
- Max Citation Score: 598.8112
- Similarity Product: 429.25041015434266

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test